Skip to main content

Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.

Elsevier
Publish with us

Conference speaker

Ali Khademhosseini

AK

Ali Khademhosseini

CEO and Founding Director

Terasaki Institute for Biomedical Innovation, USA

Talk Title: Engineering in precision medicine

Ali Khademhosseini is currently the CEO and Founding Director at the Terasaki Institute for Biomedical Innovation. Previously, he was a Professor of Bioengineering, Chemical Engineering and Radiology at the University of California-Los Angeles (UCLA). He joined UCLA as the Levi Knight Chair in November 2017 from Harvard University where he was Professor at Harvard Medical School (HMS) and faculty at the Harvard-MIT’s Division of Health Sciences and Technology (HST), Brigham and Women’s Hospital (BWH) and as well as associate faculty at the Wyss Institute for Biologically Inspired Engineering.

At Harvard University, he directed the Biomaterials Innovation Research Center (BIRC) a leading initiative in making engineered biomedical materials. Dr. Khademhosseini is an Associate Editor for ACS Nano. He served as the Research Highlights editor for Lab on a Chip. He is a fellow of the American Institute of Medical and Biological Engineering (AIMBE), Biomedical Engineering Society (BMES), Royal Society of Chemistry (RSC), Biomaterials Science and Engineering (FBSE), Materials Research Society (MRS),NANOSMAT Society, and American Association for the Advancement of Science (AAAS). He is also the recipient of the Mustafa Prize ($500,000 prize) and is a member of the International Academy of Medical and Biological Engineering, Royal Society of Canada and Canadian Academy of Engineering, and National Academy of Inventors. He is an author on >680 peer-reviewed journal articles, editorials and review papers, >70 book chapters/edited books and >50 patents/patent applications. He has been cited >103,600 times and has an H-index of 162. He has made seminal contributions to modifying hydrogels and developing novel biomaterial solutions for addressing pressing problems in healthcare. He has founded 3 companies, Omeat, Obsidio Medical which is recently acqiured by Boston Scientific and Biorae. He received his Ph.D. in bioengineering from MIT (2005), and MASc (2001) and BASc (1999) degrees from University of Toronto both in chemical engineering.